Wyeth Ziac sales will be spurred by upcoming JNC VI guidelines, exec predicts at Oppenheimer conference.
Executive Summary
WYETH PREDICTS SPUR TO ZIAC SALES FROM UPCOMING JNC VI GUIDELINES on the management of hypertension, Wyeth-Ayerst Pharmaceuticals North America President Joseph Mahady told an Oppenheimer & Co. health care conference in New York City Oct. 28. Wyeth believes that the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure "will come out in favor of low dose beta blocker/diuretic as initial therapy," Mahady said. The JNC VI guidelines will be released Nov. 6. Wyeth markets the beta blocker bisoprolol as Zebeta and in combination with hydrochlorothiazide as Ziac.